Form 4: Assertio Holdings Acquired by Zydus in $23.50 Cash Deal

Director David Matthew Stark reports the disposal of all equity holdings following the completion of Assertio Holdings' merger with Zydus.

Summary

• Assertio Holdings, Inc. (ASRT) completed its merger with Zydus Worldwide DMCC on June 16, 2026.
• All outstanding shares of common stock were cancelled and converted into the right to receive $23.50 per share in cash.
• Reporting person David Matthew Stark disposed of 11,420 shares of common stock as part of the transaction.
• Outstanding stock options with exercise prices below the $23.50 offer price were cancelled and converted into cash payments based on the spread.
• Stock options with exercise prices equal to or greater than the offer price were cancelled without payment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event as it marks the conclusion of the company's life as a public entity via a completed merger.

Positives

• Shareholders received a cash exit at $23.50 per share.
• The merger provides immediate liquidity for equity holders.

Negatives

• Stock options with exercise prices of $15.15 and $9.2565 were cancelled as part of the merger process.
• The company is no longer a publicly traded entity following the merger.

Risks

• The company has ceased to be an independent public entity, eliminating future growth potential for current shareholders.

Future Outlook

The company has been acquired and is now a wholly owned subsidiary of Zydus Worldwide DMCC; no further independent guidance is provided.

Industry Context

StockSavvy.ai notes that this acquisition represents a consolidation trend in the pharmaceutical sector, where larger entities like Zydus are absorbing smaller, specialized firms to expand their product portfolios.

Comparison to Industry Standards

• The $23.50 cash-out price represents the final valuation for shareholders in this M&A event.
• The treatment of unvested RSUs and in-the-money options is consistent with standard change-in-control provisions in pharmaceutical merger agreements.

Stakeholder Impact

• Shareholders receive cash consideration for their holdings.
• Employees and management transition to a subsidiary structure under Zydus.

Next Steps

• Delisting of Assertio Holdings common stock from public exchanges.

Key Dates

Keywords

ASRT, Assertio Holdings, Merger, Acquisition, Zydus, Form 4, Insider Transaction